These include the concomitant administration of immunotherapy with high doses of radiation applied to lymph nodes which can affect its immune function, and subsequently the anti-tumor immune response, the enrollment of a PD-L1 unselected patients, and the incorporation of both p16-negative and p16-positive tumors, as p16-positive tumors tend to have higher sensitivity to CRT and better overall prognosis (7). Here, CD274 is linked to neoplasm.